BIOHAVEN LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.72 USD | +0.58% |
|
-.--% | -14.21% |
Financials (USD)
| Sales 2024 * | 10.01M | Sales 2025 * | 14.39M | Capitalization | 3.1B |
|---|---|---|---|---|---|
| Net income 2024 * | -633M | Net income 2025 * | -627M | EV / Sales 2024 * | 256 x |
| Net cash position 2024 * | 535M | Net cash position 2025 * | 676M | EV / Sales 2025 * | 168 x |
| P/E ratio 2024 * |
-4.82
x | P/E ratio 2025 * |
-5.46
x | Employees | 239 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.87% |
More Fundamentals
* Assessed data
More news
More recommendations
More news
| 1 day | +0.58% | ||
| Current month | +4.62% | ||
| 1 month | -5.36% | ||
| 3 months | -23.72% | ||
| 6 months | +10.20% | ||
| Current year | -14.21% |
1 week
26.80
39.84
1 month
26.8042.19
Current year
26.8062.21
1 year
16.4562.21
3 years
5.5462.21
5 years
5.5462.21
10 years
5.5462.21
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 1,487 M€ | +7.77% | - | |
| 0.02% | 746 M€ | -.--% | - | |
| 0.01% | 9 M€ | +9.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 35.1 | -0.37% | 1,399,398 |
| 24-05-30 | 35.23 | +6.21% | 1,999,508 |
| 24-05-29 | 33.17 | -12.57% | 7,951,604 |
| 24-05-28 | 37.94 | +3.32% | 2,027,687 |
| 24-05-24 | 36.72 | +0.58% | 1,406,616 |
End-of-day quote Nyse, May 23, 2024
More quotes
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
Calendar
2024-07-28
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
35.1
USD
Average target price
56.89
USD
Spread / Average Target
+62.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.21% | 3.1B | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- BHVN Stock
